JP2019162150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019162150A5 JP2019162150A5 JP2019114273A JP2019114273A JP2019162150A5 JP 2019162150 A5 JP2019162150 A5 JP 2019162150A5 JP 2019114273 A JP2019114273 A JP 2019114273A JP 2019114273 A JP2019114273 A JP 2019114273A JP 2019162150 A5 JP2019162150 A5 JP 2019162150A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- gene
- cell carcinoma
- renal cell
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 24
- 238000000034 method Methods 0.000 claims 23
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 15
- 102100020997 Fractalkine Human genes 0.000 claims 12
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims 12
- 108091058560 IL8 Proteins 0.000 claims 11
- 102000004889 Interleukin-6 Human genes 0.000 claims 11
- 108090001005 Interleukin-6 Proteins 0.000 claims 11
- 102000004890 Interleukin-8 Human genes 0.000 claims 11
- 108090001007 Interleukin-8 Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 8
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims 8
- 108010045483 HLA-DPB1 antigen Proteins 0.000 claims 8
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 8
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 claims 8
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 claims 8
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 6
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 6
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 6
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 claims 5
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 claims 5
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 claims 5
- 230000002596 correlated effect Effects 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 4
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 4
- 101001003581 Homo sapiens Lamin-B1 Proteins 0.000 claims 4
- 102100026517 Lamin-B1 Human genes 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 4
- 230000017074 necrotic cell death Effects 0.000 claims 4
- 230000008595 infiltration Effects 0.000 claims 3
- 238000001764 infiltration Methods 0.000 claims 3
- 238000010606 normalization Methods 0.000 claims 3
- 102100036517 Apolipoprotein L domain-containing protein 1 Human genes 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100027641 DNA-binding protein inhibitor ID-1 Human genes 0.000 claims 1
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims 1
- 101000928701 Homo sapiens Apolipoprotein L domain-containing protein 1 Proteins 0.000 claims 1
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 claims 1
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 claims 1
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 claims 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 claims 1
- 101001126234 Homo sapiens Phospholipid phosphatase 3 Proteins 0.000 claims 1
- 101000971400 Homo sapiens Protein kinase C eta type Proteins 0.000 claims 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 claims 1
- 102100034850 Peptidyl-prolyl cis-trans isomerase G Human genes 0.000 claims 1
- 102100030450 Phospholipid phosphatase 3 Human genes 0.000 claims 1
- 102100021556 Protein kinase C eta type Human genes 0.000 claims 1
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112234A JP7385630B2 (ja) | 2010-01-11 | 2021-07-06 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29403810P | 2010-01-11 | 2010-01-11 | |
| US61/294,038 | 2010-01-11 | ||
| US34623010P | 2010-05-19 | 2010-05-19 | |
| US61/346,230 | 2010-05-19 | ||
| JP2017080314A JP6546214B2 (ja) | 2010-01-11 | 2017-04-14 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080314A Division JP6546214B2 (ja) | 2010-01-11 | 2017-04-14 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112234A Division JP7385630B2 (ja) | 2010-01-11 | 2021-07-06 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019162150A JP2019162150A (ja) | 2019-09-26 |
| JP2019162150A5 true JP2019162150A5 (enExample) | 2020-01-09 |
| JP7307602B2 JP7307602B2 (ja) | 2023-07-12 |
Family
ID=44258831
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548188A Active JP6286124B2 (ja) | 2010-01-11 | 2011-01-07 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2016041689A Pending JP2016174600A (ja) | 2010-01-11 | 2016-03-04 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2017080314A Active JP6546214B2 (ja) | 2010-01-11 | 2017-04-14 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2019114273A Active JP7307602B2 (ja) | 2010-01-11 | 2019-06-20 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2021112234A Active JP7385630B2 (ja) | 2010-01-11 | 2021-07-06 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548188A Active JP6286124B2 (ja) | 2010-01-11 | 2011-01-07 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2016041689A Pending JP2016174600A (ja) | 2010-01-11 | 2016-03-04 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2017080314A Active JP6546214B2 (ja) | 2010-01-11 | 2017-04-14 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112234A Active JP7385630B2 (ja) | 2010-01-11 | 2021-07-06 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9551034B2 (enExample) |
| EP (5) | EP3178944B1 (enExample) |
| JP (5) | JP6286124B2 (enExample) |
| AU (1) | AU2011203977B2 (enExample) |
| CA (3) | CA3128103C (enExample) |
| DK (1) | DK3178944T3 (enExample) |
| ES (2) | ES3027507T3 (enExample) |
| IL (6) | IL219978A (enExample) |
| MX (3) | MX341866B (enExample) |
| NZ (4) | NZ719474A (enExample) |
| SG (1) | SG181806A1 (enExample) |
| WO (1) | WO2011085263A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG181806A1 (en) | 2010-01-11 | 2012-07-30 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| EP3147373B1 (en) | 2010-07-27 | 2019-05-15 | Genomic Health, Inc. | Method for using gene expression to determine prognosis of prostate cancer |
| SG187045A1 (en) | 2010-08-13 | 2013-02-28 | Somalogic Inc | Pancreatic cancer biomarkers and uses thereof |
| WO2013016673A2 (en) * | 2011-07-27 | 2013-01-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma |
| US20130065782A1 (en) * | 2011-08-22 | 2013-03-14 | Somalogic, Inc. | Renal Cell Carcinoma Biomarkers and Uses Thereof |
| CN104136629B (zh) * | 2011-10-24 | 2021-08-24 | 圣诺康生命科学公司 | 碳酸酐酶ix相关标记和其用途 |
| EP3179393B1 (en) | 2012-01-31 | 2020-07-08 | Genomic Health, Inc. | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| AU2014274135B2 (en) * | 2013-05-30 | 2020-04-09 | Genomic Health, Inc. | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
| US11015190B2 (en) * | 2013-09-17 | 2021-05-25 | Lucence Life Sciences Pte Ltd | Method of treating a patient having renal cancer |
| US10731163B2 (en) * | 2014-09-02 | 2020-08-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Oligonucleotide targeted to the A20-3′ untranslated region |
| JP6638128B2 (ja) * | 2014-10-30 | 2020-01-29 | 公立大学法人福島県立医科大学 | 腎がんの悪性度の検査マーカー及び検査方法 |
| US20180044736A1 (en) * | 2015-02-03 | 2018-02-15 | Cedars-Sinai Medical Center | Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer |
| GB201616912D0 (en) | 2016-10-05 | 2016-11-16 | University Of East Anglia | Classification of cancer |
| WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2018161027A1 (en) * | 2017-03-03 | 2018-09-07 | Oregon State University | Antisense antibacterial compounds and methods |
| US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| US11335464B2 (en) * | 2018-01-12 | 2022-05-17 | Siemens Medical Solutions Usa, Inc. | Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making |
| US11427873B2 (en) * | 2018-08-10 | 2022-08-30 | Omniseq, Inc. | Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade |
| RU2747746C2 (ru) * | 2018-10-24 | 2021-05-13 | Общество с ограниченной ответственностью «Онкобокс» | Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки |
| EP3914711A2 (en) | 2019-01-23 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| US20220364178A1 (en) * | 2019-08-14 | 2022-11-17 | University Of Massachusetts | Urinary rna signatures in renal cell carcinoma (rcc) |
| MX2023009987A (es) | 2021-02-26 | 2023-09-06 | Regeneron Pharma | Tratamiento de la inflamacion con glucocorticoides e inhibidores de angiopoyetina tipo 7 (angptl7). |
| CN113025716A (zh) * | 2021-03-02 | 2021-06-25 | 北京大学第一医院 | 一种用于人肿瘤分级的基因组合及其用途 |
| CN113817816A (zh) * | 2021-10-08 | 2021-12-21 | 济南艾迪康医学检验中心有限公司 | 检测epas1基因突变的引物、试剂盒和方法 |
| WO2023080900A1 (en) * | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| CN118711678B (zh) * | 2024-08-22 | 2025-12-12 | 暨南大学附属第一医院（广州华侨医院） | 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US7135314B1 (en) | 1997-04-17 | 2006-11-14 | Cell Therapeutics, Inc. | Human phosphatidic acid phosphatase |
| ES2323220T3 (es) * | 2000-01-13 | 2009-07-09 | Genentech, Inc. | Polipeptidos humanos stra6. |
| DE10126344A1 (de) | 2000-07-14 | 2002-01-24 | Max Planck Gesellschaft | Apoptose-induzierende DNA-Sequenzen |
| AU2001294842A1 (en) * | 2000-09-28 | 2002-04-08 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
| WO2002074237A2 (en) * | 2001-03-19 | 2002-09-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
| WO2002079411A2 (en) * | 2001-03-29 | 2002-10-10 | Van Andel Institute | Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification |
| ATE503023T1 (de) | 2001-06-18 | 2011-04-15 | Rosetta Inpharmatics Llc | Diagnose und prognose von brustkrebspatientinnen |
| US7470509B2 (en) | 2002-02-08 | 2008-12-30 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer |
| WO2003078662A1 (en) | 2002-03-13 | 2003-09-25 | Genomic Health | Gene expression profiling in biopsied tumor tissues |
| WO2004032842A2 (en) | 2002-10-04 | 2004-04-22 | Van Andel Research Institute | Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers |
| CA2505416A1 (en) | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| EP1618218A2 (en) | 2003-04-29 | 2006-01-25 | Wyeth | Methods for prognosis and treatment of solid tumors |
| JP4680898B2 (ja) | 2003-06-24 | 2011-05-11 | ジェノミック ヘルス， インコーポレイテッド | 癌再発の可能性の予測 |
| BRPI0412110A (pt) | 2003-07-02 | 2006-11-21 | Novartis Ag | genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos |
| US20050002904A1 (en) * | 2003-07-03 | 2005-01-06 | Wary Kishore K. | Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
| WO2005008213A2 (en) | 2003-07-10 | 2005-01-27 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| WO2005024603A2 (en) | 2003-09-10 | 2005-03-17 | The Board Of Regents Of The University Of Texas System | Methods for detecting, diagnosing and treating human renal cell carcinoma |
| JP2005211023A (ja) * | 2004-01-30 | 2005-08-11 | Hayashibara Biochem Lab Inc | 腎細胞癌の転移若しくは再発の可能性を予測する方法 |
| US20070224596A1 (en) * | 2004-04-09 | 2007-09-27 | Mariana Nacht | Compositions and methods for the modifying hypoxia induced gene regulation |
| EP2947160B1 (en) | 2004-04-09 | 2017-07-12 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| CA2568405A1 (en) * | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Biomarkers for monitoring inhibition of impdh pathway |
| US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| WO2006066071A2 (en) * | 2004-12-17 | 2006-06-22 | Mayo Foundation For Medical Education And Research | Prognosis of renal cell carcinoma |
| US20090258002A1 (en) * | 2005-02-01 | 2009-10-15 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers for Tissue Status |
| WO2006089185A2 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | Pharmacogenomic markers for prognosis of solid tumors |
| WO2006124836A1 (en) | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
| WO2006124022A1 (en) | 2005-05-13 | 2006-11-23 | Vanandel Research Institute | Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma |
| US20070037186A1 (en) * | 2005-05-20 | 2007-02-15 | Yuqiu Jiang | Thyroid fine needle aspiration molecular assay |
| EP1899486A4 (en) | 2005-06-08 | 2009-07-22 | Millennium Pharm Inc | METHOD FOR IDENTIFYING, ASSESSING AND TREATING PATIENTS IN CANCER THERAPY |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP1907858A4 (en) | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| CN101228134A (zh) | 2005-06-15 | 2008-07-23 | 辉瑞有限公司 | 用作杀寄生虫剂的取代芳基吡唑 |
| EP2404998B1 (en) * | 2005-09-02 | 2015-11-11 | Kyoto University | Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient |
| WO2007030882A1 (en) | 2005-09-14 | 2007-03-22 | Human Genetic Signatures Pty Ltd | Assay for a health state |
| EP2332984A3 (en) | 2005-09-30 | 2011-10-12 | Universiteit Maastricht | Tumor angiogenesis associated genes and a method for their identification |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| CN101336300A (zh) | 2005-12-16 | 2008-12-31 | 健泰科生物技术公司 | 神经胶质瘤的诊断、预后和治疗方法 |
| WO2007146668A2 (en) * | 2006-06-06 | 2007-12-21 | University Of Massachusetts | Use of imp3 as a prognostic marker for cancer |
| CA2660275A1 (en) * | 2006-08-10 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| WO2008021115A2 (en) | 2006-08-14 | 2008-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| US9034574B2 (en) | 2006-12-27 | 2015-05-19 | The Johns Hopkins University | Agents for reversing epigenetic silencing of genes |
| US20080286273A1 (en) | 2007-05-02 | 2008-11-20 | Siemens Medical Solutions Usa, Inc. | Knowledge-Based Proliferation Signatures and Methods of Use |
| EP1990417A1 (en) | 2007-05-11 | 2008-11-12 | Universität Bayreuth | Archaeal plasmid vector system |
| WO2009105640A1 (en) | 2008-02-22 | 2009-08-27 | Virginia Commonwealth University | Signatures associated with rejection or recurrence of cancer |
| EP3467123A3 (en) | 2008-11-17 | 2019-07-31 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
| US20120142553A1 (en) * | 2009-06-26 | 2012-06-07 | Franciscus Petrus Smit | Molecular Markers in Kidney Cancer |
| ES2735993T3 (es) | 2009-11-23 | 2019-12-23 | Genomic Health Inc | Métodos para predecir el resultado clínico del cáncer |
| SG181806A1 (en) | 2010-01-11 | 2012-07-30 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| BR112013032232A2 (pt) | 2011-06-16 | 2016-09-20 | Caris Life Sciences Switzerland Holdings S A R L | método de caracterização de câncer através do uso de biomarcador de ácido nucleico |
| US20130065782A1 (en) | 2011-08-22 | 2013-03-14 | Somalogic, Inc. | Renal Cell Carcinoma Biomarkers and Uses Thereof |
-
2011
- 2011-01-07 SG SG2012045142A patent/SG181806A1/en unknown
- 2011-01-07 EP EP17153152.8A patent/EP3178944B1/en active Active
- 2011-01-07 US US12/987,023 patent/US9551034B2/en active Active
- 2011-01-07 MX MX2012007882A patent/MX341866B/es active IP Right Grant
- 2011-01-07 CA CA3128103A patent/CA3128103C/en active Active
- 2011-01-07 JP JP2012548188A patent/JP6286124B2/ja active Active
- 2011-01-07 WO PCT/US2011/020596 patent/WO2011085263A2/en not_active Ceased
- 2011-01-07 ES ES20210111T patent/ES3027507T3/es active Active
- 2011-01-07 AU AU2011203977A patent/AU2011203977B2/en active Active
- 2011-01-07 ES ES17153152T patent/ES2741379T3/es active Active
- 2011-01-07 NZ NZ719474A patent/NZ719474A/en unknown
- 2011-01-07 EP EP20210111.9A patent/EP3831964B1/en active Active
- 2011-01-07 EP EP19173150.4A patent/EP3561078A1/en not_active Withdrawn
- 2011-01-07 NZ NZ61700311A patent/NZ617003A/en unknown
- 2011-01-07 DK DK17153152.8T patent/DK3178944T3/da active
- 2011-01-07 EP EP11732245.3A patent/EP2524055A4/en not_active Withdrawn
- 2011-01-07 NZ NZ600268A patent/NZ600268A/en unknown
- 2011-01-07 CA CA3256492A patent/CA3256492A1/en active Pending
- 2011-01-07 MX MX2016010666A patent/MX375138B/es unknown
- 2011-01-07 EP EP15203193.6A patent/EP3029155A3/en not_active Withdrawn
- 2011-01-07 CA CA2783858A patent/CA2783858C/en active Active
- 2011-01-07 NZ NZ705645A patent/NZ705645A/en unknown
-
2012
- 2012-05-24 IL IL219978A patent/IL219978A/en active IP Right Grant
- 2012-07-05 MX MX2020009704A patent/MX2020009704A/es unknown
-
2016
- 2016-03-04 JP JP2016041689A patent/JP2016174600A/ja active Pending
- 2016-12-05 US US15/368,979 patent/US10892038B2/en active Active
-
2017
- 2017-04-06 IL IL251635A patent/IL251635B/en active IP Right Grant
- 2017-04-14 JP JP2017080314A patent/JP6546214B2/ja active Active
- 2017-12-14 IL IL256335A patent/IL256335B/en active IP Right Grant
-
2018
- 2018-10-03 IL IL26210018A patent/IL262100B/en active IP Right Grant
-
2019
- 2019-06-20 JP JP2019114273A patent/JP7307602B2/ja active Active
- 2019-10-24 IL IL270151A patent/IL270151B/en active IP Right Grant
-
2020
- 2020-11-19 US US16/952,566 patent/US11776664B2/en active Active
-
2021
- 2021-02-07 IL IL280689A patent/IL280689B/en unknown
- 2021-07-06 JP JP2021112234A patent/JP7385630B2/ja active Active
-
2023
- 2023-08-23 US US18/454,312 patent/US12412642B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019162150A5 (enExample) | ||
| JP2016174600A5 (enExample) | ||
| JP2021177761A5 (enExample) | ||
| JP2020143146A5 (enExample) | ||
| Fraser et al. | Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer | |
| Sato et al. | Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease | |
| Duenas et al. | PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non‐muscle invasive tumors | |
| Lurje et al. | Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer | |
| Su et al. | Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis | |
| JP2008546387A5 (enExample) | ||
| CN105940117A (zh) | 前列腺癌分类 | |
| JP2014509189A5 (enExample) | ||
| NZ719474A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| Sekar et al. | Evaluation of p53, HoxD10, and E‐cadherin status in breast cancer and correlation with histological grade and other prognostic factors | |
| Zheng et al. | Plasma minichromosome maintenance complex component 6 is a novel biomarker for hepatocellular carcinoma patients | |
| Peng et al. | Loss of EphB6 protein expression in human colorectal cancer correlates with poor prognosis | |
| CN110004226A (zh) | 一种基于直肠癌转录组基因及甲基化联合分析预测预后的方法及模型应用 | |
| Zuberi et al. | The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer | |
| JP2017516501A5 (enExample) | ||
| Rexin et al. | The immune checkpoint molecule CD200 is associated with tumor grading and metastasis in bladder cancer | |
| Contreras‐Sanz et al. | Recent progress with next‐generation biomarkers in muscle‐invasive bladder cancer | |
| Kindt et al. | Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas | |
| Zhao et al. | Prediction of survival of diffuse large B‐cell lymphoma patients via the expression of three inflammatory genes | |
| JP2010523134A (ja) | Ｅｇｆｒ／ｃｓｆ−１／ｃａｉｘ発現に基づき非小細胞肺癌の化学療法計画および生存余命を決定する方法 | |
| WO2006034456A3 (en) | Compositions and methods for detecting and treating tumors |